News und Analysen
Evotec: Nur eine Korrektur oder droht Schlimmeres?
Irgendwann trifft es auch die beste Aktie. In der letzten Handelswoche war nun Evotec an der Reihe. Nach einer monatelangen Rally ab Februar 2016 im Zuge derer der Kurs Bitcoin-artig um fast 700 %....
So, This Is What the End of Obamacare Looks Like
For better or worse, the Affordable Care Act (ACA) has been the law of the land since it was signed into law in March 2010 and officially was enacted in the individual insurance markets in 2014.In....
So, This Is What the End of Obamacare Looks Like
For better or worse, the Affordable Care Act (ACA) has been the law of the land since it was signed into law in March 2010 and officially was enacted in the individual insurance markets in 2014.In....
Better Buy: Exelixis, Inc. vs. Novartis AG
Novartis (NYSE: NVS) stands out as one of the biggest pharma companies with a broad array of products, including several of the most powerful cancer drugs on the market. Exelixis (NASDAQ: EXEL)....
5 Irresistible Reasons to Buy Celgene Stock Right Now (Hint: 1 Is that It's Dirt Cheap)
If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing....
3 Top Biotech Stocks for 2018
Biotech stocks have been outstanding growth vehicles over the past six-plus years. The industry is still in "hypergrowth" mode because of a number of favorable tailwinds, such as an aging global....
3 Biotech Stocks That Soared This Week: Are They Buys?
Earnings season continued to be in high gear this week. Positive quarterly results helped propel several biotech stocks higher over the last few days. Others jumped because of good news for their....
3 Growth Stocks for Farsighted Investors
Investing in so-called growth stocks can be as exciting as it is frustrating. All too often, investors who own growth stocks panic when they realize that the road to market-beating gains is....
3 Growth Stocks for Farsighted Investors
Investing in so-called growth stocks can be as exciting as it is frustrating. All too often, investors who own growth stocks panic when they realize that the road to market-beating gains is....
3 Growth Stocks for Farsighted Investors
Investing in so-called growth stocks can be as exciting as it is frustrating. All too often, investors who own growth stocks panic when they realize that the road to market-beating gains is....
Obamacare Was Destined to Fail, Even Without Trump
In case you missed it, open enrollment for the Affordable Care Act's (ACA) fifth year is underway, through Dec. 15, 2017, or perhaps a bit longer in select states. The upcoming year of enrollment....
Obamacare Was Destined to Fail, Even Without Trump
In case you missed it, open enrollment for the Affordable Care Act's (ACA) fifth year is underway, through Dec. 15, 2017, or perhaps a bit longer in select states. The upcoming year of enrollment....
It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval
Some thought this day would never arrive. After two prior failed attempts, Dynavax Technologies (NASDAQ: DVAX) finally won approval for hepatitis B vaccine Heplisav-B. The company announced the....
Better Buy: Acadia Pharmaceuticals vs. Biogen
A potential rising star or an established leader? That's pretty much the choice for investors considering whether to buy Acadia Pharmaceuticals (NASDAQ: ACAD) or Biogen (NASDAQ: BIIB) stock.So far....
Better Buy: Acadia Pharmaceuticals vs. Biogen
A potential rising star or an established leader? That's pretty much the choice for investors considering whether to buy Acadia Pharmaceuticals (NASDAQ: ACAD) or Biogen (NASDAQ: BIIB) stock.So far....
Better Buy: Acadia Pharmaceuticals vs. Biogen
A potential rising star or an established leader? That's pretty much the choice for investors considering whether to buy Acadia Pharmaceuticals (NASDAQ: ACAD) or Biogen (NASDAQ: BIIB) stock.So far....
Puma Biotechnology Is Down 19% -- Is Its Stock a Bargain?
Despite a fairly strong third-quarter earnings release that hit the wires after the bell Thursday, mid-cap biotech Puma Biotechnology's (NASDAQ: PBYI) shares got pummeled today. Specifically,....
Momenta Pharmaceuticals, Inc.'s Rough Month
Momenta Pharmaceuticals (NASDAQ: MNTA) has had a rough month or so after seeing Mylan (NASDAQ: MYL) pass it up to get the first approval of a generic version of Teva Pharmaceutical's (NYSE: TEVA)....
Why Immunomedics, Inc. Jumped Higher Today
Immunomedics (NASDAQ: IMMU) is up 19% at 2:21 p.m. EST, after announcing a new CEO following the closing bell yesterday. The company also announced fiscal first-quarter earnings, but the jump in....
This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today
Despite already rewarding investors with more than a 100% return this year, shares of Omeros Corporation (NASDAQ: OMER) are charging 33.3% higher at 1:45 p.m. EST Friday following the release of....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 31 octobre 2017
Le 10 novembre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
7 Things AbbVie's Top Executives Just Said That You'll Want to Know
It's a good time to be AbbVie (NYSE: ABBV). And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. The company reported a strong....
Ionis Pharmaceuticals' Earnings Results Fuel Volatility
Ionis Pharmaceuticals (NASDAQ: IONS) reported third-quarter financials that were better than hoped on Tuesday, but the worry of slowing U.S. sales of Spinraza, a rare disease drug that's licensed....
Why Macy's, Hostess Brands, and Perrigo Jumped Today
The stock market lost ground Thursday as investors reacted negatively to news regarding proposed U.S. corporate and individual income tax cuts. Reports surfaced that the Senate version of tax....
ImmunoGen, Inc. Moves Forward
Like most biotechs without a drug generating revenue, ImmunoGen's (NASDAQ: IMGN) third-quarter earnings were a review of what it's accomplished and a look at what investors can expect in the....